Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Moderna's EV/EBITDA was 23.4× on Oct 31, 2023, against 3.2× a year earlier. Over the last 3 years it ranged from 2.4× to 199.5×, with a median of 7.0×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Oct 31, 2023 | 23.4× | +18.9 |
| 2022 | Dec 30, 2022 | 4.5× | −7.6 |
| 2021 | Dec 31, 2021 | 12.1× | – |
See a number that looks wrong?